vs
ANI PHARMACEUTICALS INC（ANIP）与Rubrik, Inc.（RBRK）财务数据对比。点击上方公司名可切换其他公司
Rubrik, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.4倍（$350.2M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -18.2%，领先29.4%），Rubrik, Inc.同比增速更快（48.3% vs 29.6%），Rubrik, Inc.自由现金流更多（$80.7M vs $29.1M）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Rubrik是总部位于美国加利福尼亚州帕洛阿尔托的云数据管理与数据安全企业，成立于2014年1月，专注于为客户提供云环境下的数据管理、安全防护相关解决方案，2024年4月在纽约证券交易所上市。
ANIP vs RBRK — 直观对比
营收规模更大
RBRK
是对方的1.4倍
$247.1M
营收增速更快
RBRK
高出18.6%
29.6%
净利率更高
ANIP
高出29.4%
-18.2%
自由现金流更多
RBRK
多$51.6M
$29.1M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $350.2M |
| 净利润 | $27.5M | $-63.8M |
| 毛利率 | — | 80.5% |
| 营业利润率 | 14.1% | -21.6% |
| 净利率 | 11.1% | -18.2% |
| 营收同比 | 29.6% | 48.3% |
| 净利润同比 | 367.5% | 51.2% |
| 每股收益（稀释后） | $1.14 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRBRK
| Q4 25 | $247.1M | $350.2M | ||
| Q3 25 | $227.8M | $309.9M | ||
| Q2 25 | $211.4M | $278.5M | ||
| Q1 25 | $197.1M | $258.1M | ||
| Q4 24 | $190.6M | $236.2M | ||
| Q3 24 | $148.3M | $205.0M | ||
| Q2 24 | $138.0M | $187.3M | ||
| Q1 24 | $137.4M | — |
净利润ANIPRBRK
| Q4 25 | $27.5M | $-63.8M | ||
| Q3 25 | $26.6M | $-95.9M | ||
| Q2 25 | $8.5M | $-102.1M | ||
| Q1 25 | $15.7M | $-114.9M | ||
| Q4 24 | $-10.3M | $-130.9M | ||
| Q3 24 | $-24.2M | $-176.9M | ||
| Q2 24 | $-2.3M | $-732.1M | ||
| Q1 24 | $18.2M | — |
毛利率ANIPRBRK
| Q4 25 | — | 80.5% | ||
| Q3 25 | — | 79.5% | ||
| Q2 25 | — | 78.3% | ||
| Q1 25 | — | 77.4% | ||
| Q4 24 | — | 76.2% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 48.8% | ||
| Q1 24 | — | — |
营业利润率ANIPRBRK
| Q4 25 | 14.1% | -21.6% | ||
| Q3 25 | 15.9% | -30.5% | ||
| Q2 25 | 6.6% | -33.4% | ||
| Q1 25 | 13.3% | -45.0% | ||
| Q4 24 | -2.3% | -52.8% | ||
| Q3 24 | -13.8% | -82.1% | ||
| Q2 24 | 3.7% | -387.0% | ||
| Q1 24 | 14.8% | — |
净利率ANIPRBRK
| Q4 25 | 11.1% | -18.2% | ||
| Q3 25 | 11.7% | -31.0% | ||
| Q2 25 | 4.0% | -36.7% | ||
| Q1 25 | 8.0% | -44.5% | ||
| Q4 24 | -5.4% | -55.4% | ||
| Q3 24 | -16.3% | -86.3% | ||
| Q2 24 | -1.7% | -390.8% | ||
| Q1 24 | 13.2% | — |
每股收益（稀释后）ANIPRBRK
| Q4 25 | $1.14 | $-0.32 | ||
| Q3 25 | $1.13 | $-0.49 | ||
| Q2 25 | $0.36 | $-0.53 | ||
| Q1 25 | $0.69 | $5.69 | ||
| Q4 24 | $-0.45 | $-0.71 | ||
| Q3 24 | $-1.27 | $-0.98 | ||
| Q2 24 | $-0.14 | $-11.48 | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $307.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $-524.4M |
| 总资产 | $1.4B | $2.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRBRK
| Q4 25 | $285.6M | $307.1M | ||
| Q3 25 | $262.6M | $322.7M | ||
| Q2 25 | $217.8M | $284.0M | ||
| Q1 25 | $149.8M | $186.3M | ||
| Q4 24 | $144.9M | $103.9M | ||
| Q3 24 | $145.0M | $142.3M | ||
| Q2 24 | $240.1M | $502.6M | ||
| Q1 24 | $228.6M | — |
股东权益ANIPRBRK
| Q4 25 | $540.7M | $-524.4M | ||
| Q3 25 | $505.8M | $-564.3M | ||
| Q2 25 | $436.8M | $-556.5M | ||
| Q1 25 | $418.6M | $-553.7M | ||
| Q4 24 | $403.7M | $-521.1M | ||
| Q3 24 | $405.9M | $-499.3M | ||
| Q2 24 | $455.8M | $-514.6M | ||
| Q1 24 | $452.0M | — |
总资产ANIPRBRK
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $85.5M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $80.7M |
| 自由现金流率自由现金流/营收 | 11.8% | 23.1% |
| 资本支出强度资本支出/营收 | 0.5% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $256.8M |
8季度趋势，按日历期对齐
经营现金流ANIPRBRK
| Q4 25 | $30.4M | $85.5M | ||
| Q3 25 | $44.1M | $64.7M | ||
| Q2 25 | $75.8M | $39.7M | ||
| Q1 25 | $35.0M | $83.6M | ||
| Q4 24 | $15.9M | $23.1M | ||
| Q3 24 | $12.5M | $-27.1M | ||
| Q2 24 | $17.4M | $-31.4M | ||
| Q1 24 | $18.3M | — |
自由现金流ANIPRBRK
| Q4 25 | $29.1M | $80.7M | ||
| Q3 25 | $38.0M | $61.2M | ||
| Q2 25 | $71.8M | $36.8M | ||
| Q1 25 | $32.5M | $78.0M | ||
| Q4 24 | $13.5M | $18.0M | ||
| Q3 24 | $7.7M | $-29.7M | ||
| Q2 24 | $13.0M | $-35.0M | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPRBRK
| Q4 25 | 11.8% | 23.1% | ||
| Q3 25 | 16.7% | 19.8% | ||
| Q2 25 | 34.0% | 13.2% | ||
| Q1 25 | 16.5% | 30.2% | ||
| Q4 24 | 7.1% | 7.6% | ||
| Q3 24 | 5.2% | -14.5% | ||
| Q2 24 | 9.4% | -18.7% | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPRBRK
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.0% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 3.2% | 1.9% | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPRBRK
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RBRK
| Subscription And Circulation | $336.4M | 96% |
| Other | $12.3M | 4% |
| Software And Services | $4.9M | 1% |
| Maintenance | $1.5M | 0% |
